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STAMPEDE (ClinicalTrials.gov identifier NCT00268476) is a
flagship multiarm, multistage, open-label, randomised
controlled trial in the United Kingdom and Switzerland
evaluating the combination of novel treatment strategies
with androgen deprivation therapy (ADT). This includes
assessing whether effective second-line treatments should
be used for patients commencing long-termADT for the first
time. The trial launched in October 2005 with five research
arms compared pairwise against a common control arm
(Fig. 1), and to date, >5500 men have been recruited. The
celecoxib arms were closed for lack of sufficient activity at
the second preplanned interim analysis [1]. The remaining
original arms—zoledronic acid, docetaxel, and zoledronic
acid with docetaxel—successfully recruited throughout all
interim stages and closed to recruitment in March 2013.
Primary outcome data from these original arms are
expected in mid-2015.
Introducing a new research arm within the novel multi-
arm adaptive design of STAMPEDE, rather than a separate,
competing trial, is an efficient approach with immediate
start-upat>100 sites and theuseof a shared control arm that
will give answers more quickly without adversely affecting
the timelines for the ongoing comparisons. A new* Corresponding author. MRC Clinical Trials Unit at UCL, Institute of Clinica
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).arm (arm G) of abiraterone, prednisone, and ADT was
seamlessly introduced inNovember2011 (Fig. 1), andaccrual
of >1900 patients to this randomised comparison of
abiraterone was completed in January 2014. A new arm
(arm H) considering radiotherapy (RT) to the prostate for
newly diagnosed metastatic patients was introduced in
January 2013 [2]. Now another new arm (arm J), combining
enzalutamide, abiraterone, and prednisone with ADT, is
being initiated in July 2014 throughout the United Kingdom.
2. Rationale for CYP17A1 inhibition in hormone-
sensitive disease
ADT with luteinising hormone-releasing hormone analo-
gues reduces the total androgen pool by up to 80% in a 60-
yr-old man [3]. Abiraterone is a specific CYP17A1 inhibitor
that effectively suppresses nongonadal androgen and
oestrogen synthesis [3]. Treatment of noncastrate men
with abiraterone is associated with an initial decrease in
serum testosterone, but a subsequent surge in luteinising
hormone causes an increase in gonadal androgen synthesis
that is not inhibited by currently approved doses of
abiraterone [4]. Consequently, men receiving abiraterone
1000 mg daily require concomitant effective inhibition of
gonadal steroidogenesis. Due to the inhibition of bothl Trials and Methodology, Aviation House, 125 Kingsway, London
V. This is an open access article under the CC BY-NC-ND
[(Fig._1)TD$FIG]
SOC + zoledronic acid
SOC + docetaxel
SOC + celecoxib
SOC + zoledronic acid + docetaxel
SOC + zoledronic acid + celecoxib
SOC  + (abi)*
SOC
SOC + M1/RT {M1}
SOC + (enza + abi)**
* Abiraterone
** Enzalutamide + abiraterone
Accrual - past
Accrual - future
Follow-up
A
B
C
D
E
F
G
H
J
A
B
C
D
E
F
G
H
J
Tr
ia
l a
rm
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
July 2014: Third new comparison
Fig. 1 – Accrual activity over time.
SOC = Standard-of-care = ADT (+/SRT); ADT = androgen deprivation therapy; RT = radiotherapy.
E U RO P E AN URO LOGY 6 6 ( 2 0 1 4 ) 7 9 9 – 8 0 2800CYP17A1 C17,20-lyase and 17a-hydroxylase, treatment
with abiraterone is associated with inhibition of cortisol
synthesis and a consequent rise in adrenocorticotrophic
hormone, which is associatedwith a syndrome of secondary
mineralocorticoid excess in up to 90% of patients [3].
Abiraterone has thus been developed for the treatment of
metastatic castration-resistant prostate cancer (CRPC) in
combination with prednisone or prednisolone [5].
Clinical trials demonstrating the efficacy of abiraterone in
CRPChaveconfirmedthata significantproportionof tumours
are dependent on sex steroids that persist despite castration
[5]. In addition to suppression of circulating androgens and
oestrogens, abiraterone could also inhibit CYP17A1-depen-
dent androgen synthesis by the cancer itself, although this is
harder to prove and remains speculative. In addition,
abiraterone is a weak antagonist of the androgen receptor
(AR) [6], although the clinical relevance of this remains
uncertain. In the newly diagnosed patients with M1 disease
in the control arm of STAMPEDE, the median time to
progression on castration is 12mo [7]. Consequently, there is
a clear need for treatments in addition to ADT in a high-risk
population. Potential mechanisms of castration resistance
that will be targeted by combination with abiraterone
include activation of AR signalling by residual low levels of
androgens and CYP17A1 tumoural androgen synthesis.
3. Rationale for combined castration, CYP17A1
inhibition, and androgen receptor antagonism in
hormone-sensitive disease
Enzalutamide is a rationally designed AR antagonist that is
effective in men with CRPC, including in those patients whohave progressed on bicalutamide [8]. Enzalutamide is
very well tolerated, and other than side effects related to
profound androgen suppression, there is no evidence of
overlapping side effects between abiraterone with pred-
nisolone or prednisone and enzalutamide. The combina-
tion of these agents is undergoing evaluation in a single-
arm phase 1b clinical trial in metastatic CRPC at MD
Anderson Cancer Center (ClinicalTrials.gov identifier
NCT01650194), and preliminary data suggest no in-
creased toxicity. The efficacy of the combination of
abiraterone, prednisone, and enzalutamide is being
compared with enzalutamide alone in chemotherapy-
naı¨ve metastatic CRPC, with overall survival as the
primary outcome measure (ClinicalTrials.gov identifier
NCT01949337). An industry-sponsored randomised trial
is also evaluating radiologic progression-free survival of
enzalutamide in combination with abiraterone and
prednisolone compared with placebo, abiraterone, and
prednisone in patients with CRPC and rising prostate-
specific antigen on enzalutamide (ClinicalTrials.gov iden-
tifier NCT01995513).
Translational studies suggest increased androgen syn-
thesis in patients treated with enzalutamide [9] that could
result in ‘‘outcompeting’’ of enzalutamide at the AR [6]. This
would be inhibited by combining enzalutamide with
abiraterone. Conversely, abiraterone does not completely
suppress steroids that could activate a ‘‘hypersensitive’’ or
‘‘promiscuous’’ AR; this mechanism for maintained AR
activation could be inhibited by combination with enzalu-
tamide. Consequently, there is a pressing case for agents
from these classes to be assessed synchronously for activity
and synergism in hormone-naı¨ve disease.
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Although there is the potential for greater activity in these
patients, there may be issues of toxicity or practical use of
the combination that limit any advantage.
4.1. Long-term metabolic toxicity associated with more
profound androgen suppression and concomitant glucocorticoid
administration
Limited data are available on the long-term side effects
associated with metabolic disturbances from novel endo-
crine agents, although the sequelae of castration are well
described and could be worsened by longer use of
additional endocrine treatments.
4.2. Priming of cancers to earlier development of resistance
The mechanisms of resistance to abiraterone and enzalu-
tamide are still being elucidated. Recently, a point mutation
in the AR was described that results in activation rather
than antagonism of AR signalling by enzalutamide [10].
Similarly, activation of the AR by glucocorticoids following
development of AR point mutations can occur [6]. Both
agents target ligand activation of the AR and thus could
share mechanisms of resistance, including, for example, an
increase in constitutively active AR splice variants that lack
the ligand binding domain and upregulation of the
glucocorticoid receptor thatmaintains expression of steroid
receptor–regulated genes [11]. The use of these treatments
in hormone-sensitive disease could prolong failure-free
survival but also ‘‘prime’’ the disease to earlier development
of resistance with later AR-targeting strategies, leading to a
failure to affect overall survival.
4.3. Cost
The UK list price of abiraterone is approximately £2630,
with independent estimates of cost per quality-adjusted
life-year equivalent to £46,800–50,000 [12]. The list price of
enzalutamide is currently more (approximately £3500).
Consequently, combination therapy may be prohibitively
expensive but will decrease, perhaps around the time our
data mature.
5. Trial design considerations
Overall, 1800 patients will be randomised 1:1 to the control
arm (currently ADT with additional prostate RT for N0M0
patients) or to research arm J. Patients with newly
diagnosed metastatic disease may instead be allocated to
a third arm (arm H) assessing the role of RT to the prostate
(Fig. 1) [2]. Two intermediate analyses of lack of sufficient
activity based on failure-free survival will be undertaken
and reviewed by the Independent Data Monitoring Com-
mittee (IDMC) in line with the ongoing trial design. The
IDMCwill also assess toxicity, with the first review planned
after 50 patients have been allocated to arm J and have been
on trial for just 6 wk; a further review will take place when50 patients in arm J have been on trial for approximately
6 mo. Recruitment will take up to 3 yr, with reporting of
overall survival predicted for approximately 3 yr later
(approximately 2020). An indirect comparison of the
relative efficacy of adding enzalutamide to abiraterone will
be possible through the published results of the separate
STAMPEDE ‘‘abiraterone comparison’’ (arm G); however,
the converse indirect comparison would require network
meta-analysis with relevant trials assessing addition of
enzalutamide to ADT.
6. Conclusions
The introduction of the new arm J has received the support
of investigators, patients, funders (Cancer Research UK and
the Medical Research Council), and pharmaceutical part-
ners (including Astellas and Janssen). The efficiencies
engendered by undertaking this comparison as an amend-
ment to the multiarm, multistage STAMPEDE trial should
facilitate rapid answers to the questions posed by use of this
novel combination.
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